Published in World J Gastroenterol on July 21, 2014
Colitis-associated colon cancer: Is it in your genes? World J Gastroenterol (2015) 0.77
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut (2010) 6.34
Colorectal cancer. Lancet (2005) 4.90
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2005) 3.01
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res (2005) 2.64
Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology (1992) 2.61
Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 2.44
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology (2004) 2.23
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut (2002) 2.13
The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol (2010) 1.93
Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology (1991) 1.93
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol (2012) 1.84
Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol (2008) 1.70
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65
High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol (2008) 1.64
Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology (2001) 1.63
In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol (2010) 1.61
Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut (2011) 1.61
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther (2012) 1.49
Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol (1997) 1.47
The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol (1999) 1.40
Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer (1998) 1.34
Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res (1994) 1.25
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther (2004) 1.16
Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation (2003) 1.14
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2005) 1.13
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology (2010) 1.09
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology (2010) 1.07
Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.05
The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol (1997) 1.00
Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int (2011) 0.99
Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol (1997) 0.98
Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology (2011) 0.97
Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int (2011) 0.95
Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.92
Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum (2011) 0.90
Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2010) 0.87
Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res (1998) 0.87
Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 0.85
Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study. Acta Gastroenterol Latinoam (2008) 0.84
Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl (2013) 0.83
Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis (2007) 0.83
Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol (2003) 0.83
Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis (2011) 0.82
More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis (2009) 0.82
Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci (2013) 0.82
In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig Dis Sci (2011) 0.76